2023
Psychometric Properties of the Self-Injurious Thoughts and Behaviors Interview–Short Form Among U.S. Active Duty Military Service Members and Veterans
Stanley I, Marx B, Fina B, Young-McCaughan S, Tyler H, Sloan D, Blankenship A, Dondanville K, Walker J, Boffa J, Bryan C, Brown L, Straud C, Mintz J, Abdallah C, Back S, Blount T, DeBeer B, Flanagan J, Foa E, Fox P, Fredman S, Krystal J, McDevitt-Murphy M, McGeary D, Pruiksma K, Resick P, Roache J, Shiroma P, Taylor D, Wachen J, Kaplan A, López-Roca A, Nicholson K, Schobitz R, Schrader C, Sharrieff A, Yarvis J, Litz B, Keane T, Peterson A. Psychometric Properties of the Self-Injurious Thoughts and Behaviors Interview–Short Form Among U.S. Active Duty Military Service Members and Veterans. Assessment 2023, 30: 2332-2346. PMID: 36644835, DOI: 10.1177/10731911221143979.Peer-Reviewed Original ResearchConceptsBehaviors Interview-Short FormPosttraumatic stress disorderSelf-injurious thoughtsMilitary service membersService membersDiscriminant validitySelf-report measuresInterview-based measuresSuicidal ideationSelf-report questionnairesActive duty military service membersSuicide-related thoughtsActive duty service membersPTSD symptomsStress disorderRelated constructsGood convergentConvergent validityResponse formatPsychometric propertiesSuicide risk assessmentInterrater reliabilityHigh interrater reliabilityIdeationVeterans
2022
Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode
Rhee TG, Shim SR, Forester BP, Nierenberg AA, McIntyre RS, Papakostas GI, Krystal JH, Sanacora G, Wilkinson ST. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode. JAMA Psychiatry 2022, 79: 1162-1172. PMID: 36260324, PMCID: PMC9582972, DOI: 10.1001/jamapsychiatry.2022.3352.Peer-Reviewed Original ResearchMeSH KeywordsDepressive Disorder, MajorElectroconvulsive TherapyHumansKetamineRandomized Controlled Trials as TopicSuicide, AttemptedConceptsStandardized mean differenceMajor depressive episodeSerious adverse eventsElectroconvulsive therapyAdverse eventsDepressive episodeClinical trialsDepression severityEfficacy outcomesSystematic reviewUnique adverse effect profileMeta-analyses (PRISMA) reporting guidelinesSafety of ketamineAdverse effect profileData extractionEuropean clinical trialsDiagnosis of depressionModerate methodological qualityMedical Subject Headings termsPreferred Reporting ItemsCognition/memoryRandom-effects modelSubject Headings termsAcute phaseEffect profileGenetic liability to suicidal thoughts and behaviors and risk of suicide attempt in US military veterans: moderating effects of cumulative trauma burden
Nichter B, Koller D, De Angelis F, Wang J, Girgenti M, Na P, Hill M, Norman S, Krystal J, Gelernter J, Polimanti R, Pietrzak R. Genetic liability to suicidal thoughts and behaviors and risk of suicide attempt in US military veterans: moderating effects of cumulative trauma burden. Psychological Medicine 2022, 53: 6325-6333. PMID: 36444557, DOI: 10.1017/s0033291722003646.Peer-Reviewed Original ResearchMeSH KeywordsFemaleGenome-Wide Association StudyHumansMaleRisk FactorsSuicidal IdeationSuicide, AttemptedVeteransConceptsPolygenic risk scoresUS military veteransLifetime suicide attemptsSuicide attemptsTrauma exposureTrauma burdenGenetic liabilityMilitary veteransDrug repurposing analysisPopulation-based sampleCumulative trauma exposureLifetime trauma exposureLow trauma exposureSuicide prediction modelsChronic inflammationInflammatory processNervous system developmentRisk scorePsychiatric characteristicsSuicidal behaviorExposure interactionsLarge genome-wide association studiesHigh levelsVeteransSuicidality
2021
Risk factors for suicide attempts among U.S. military veterans: A 7‐year population‐based, longitudinal cohort study
Nichter B, Stein MB, Monteith LL, Herzog S, Holliday R, Hill ML, Norman SB, Krystal JH, Pietrzak RH. Risk factors for suicide attempts among U.S. military veterans: A 7‐year population‐based, longitudinal cohort study. Suicide And Life-Threatening Behavior 2021, 52: 303-316. PMID: 34873738, DOI: 10.1111/sltb.12822.Peer-Reviewed Original Research
2007
Lamotrigine as Add-On Therapy in Schizophrenia
Goff DC, Keefe R, Citrome L, Davy K, Krystal JH, Large C, Thompson TR, Volavka J, Webster EL. Lamotrigine as Add-On Therapy in Schizophrenia. Journal Of Clinical Psychopharmacology 2007, 27: 582-589. PMID: 18004124, DOI: 10.1097/jcp.0b013e31815abf34.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnticonvulsantsAntipsychotic AgentsClozapineDiagnostic and Statistical Manual of Mental DisordersDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleDrug ResistanceDrug Therapy, CombinationFemaleHumansLamotrigineMaleMiddle AgedPatient CompliancePatient DropoutsPsychiatric Status Rating ScalesSchizophreniaSeverity of Illness IndexSuicide, AttemptedTreatment OutcomeTriazinesConceptsNegative Syndrome Scale total scoreScale total scoreAntipsychotic medicationTotal scoreTreatment groupsSchizophrenia patientsPlacebo-controlled trialPrimary end pointParallel-group trialUse of lamotrigineClinical Global ImpressionAtypical antipsychotic medicationsResidual psychotic symptomsSymptom total scoreNegative Symptoms total scoreLamotrigine augmentationLamotrigine trialsRefractory psychosisAtypical antipsychoticsCognitive composite scoreWeek 12Global ImpressionTreat samplePsychotic symptomsLamotrigine